PMID- 28223108
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20171212
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 102
IP  - 2
DP  - 2017 Apr
TI  - Tenascin C is a prognostic determinant and potential cancer-associated 
      fibroblasts marker for breast ductal carcinoma.
PG  - 262-267
LID - S0014-4800(16)30388-4 [pii]
LID - 10.1016/j.yexmp.2017.02.012 [doi]
AB  - Tenascin C (TNC) is a key of extracellular matrix glycoprotein and highly express 
      in numerous human malignancies. Herein, we attempted to clarify the 
      clinicopathological significance of TNC as a prognostic determinant of breast 
      ductal carcinoma. Then, we investigated TNC immunohistochemical expression in 150 
      breast ductal carcinomas and 27 normal breast tissue samples. Clinical relevance 
      of TNC expression and the association TNC expression with other factors related 
      to cancer-associated fibroblasts were also examined. In results, TNC expression 
      was significantly higher in breast ductal carcinoma (56.0%) than normal breast 
      tissues (25.9%). The upregulation TNC in cancer stromal were associated with pT 
      stage (P=0.003), lymph node metastasis (P=0.002) and tumor node metastasis stage 
      (P=0.001), also was correlated with an increase in tumor-associated macrophage 
      population (P<0.001). The microvessel density (MVD) was significantly higher in 
      TNC positive group than in negative group (P<0.001). In both univariate and 
      multivariate Cox regression analyses, TNC was an independent poor prognostic 
      factor for overall survival (OS) in breast ductal carcinoma patients. 
      Importantly, over-expression TNC (P<0.001), FSP1 (P<0.001), SMA (P=0.002) and 
      Vimentin (P=0.049) were significantly correlation with the lower OS (P<0.005). In 
      addition, TNC expression in breast ductal carcinoma stromal was positively 
      correlated with FSP1 (P<0.001), SMA (P=0.001) and Vimentin (P<0.001). In 
      conclusion, the high expression of TNC could be a useful cancer-associated 
      fibroblasts marker for the prediction of prognosis of breast ductal carcinoma 
      patients.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Yang, Zhaoting
AU  - Yang Z
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China.
FAU - Ni, Weidong
AU  - Ni W
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China.
FAU - Cui, Chunai
AU  - Cui C
AD  - Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China.
FAU - Fang, Longyun
AU  - Fang L
AD  - Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China; Department of Surgery, Affiliated Hospital of Yanbian 
      University, Yanji, China. Electronic address: flying036@163.com.
FAU - Xuan, Yanhua
AU  - Xuan Y
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China. Electronic address: xuanyh1@ybu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170220
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Tenascin)
SB  - IM
MH  - Biomarkers, Tumor/analysis
MH  - Breast/cytology/metabolism
MH  - Breast Neoplasms/*diagnosis/pathology
MH  - Cancer-Associated Fibroblasts/cytology/*metabolism
MH  - Carcinoma, Ductal, Breast/*diagnosis/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis/*diagnosis/pathology
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Specimen Handling
MH  - Tenascin/*analysis
OTO - NOTNLM
OT  - Breast ductal carcinoma
OT  - Cancer-associated fibroblasts
OT  - Prognostis
OT  - Tenascin C
EDAT- 2017/02/23 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/02/23 06:00
PHST- 2016/11/26 00:00 [received]
PHST- 2017/01/19 00:00 [revised]
PHST- 2017/02/04 00:00 [accepted]
PHST- 2017/02/23 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
PHST- 2017/02/23 06:00 [entrez]
AID - S0014-4800(16)30388-4 [pii]
AID - 10.1016/j.yexmp.2017.02.012 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2017 Apr;102(2):262-267. doi: 10.1016/j.yexmp.2017.02.012. Epub 
      2017 Feb 20.